Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial

Eye (Lond). 2025 Jan 13. doi: 10.1038/s41433-024-03543-x. Online ahead of print.

Authors

Jeffrey S Heier¹, Xin Zhang², Kimberly Reed³, Alyson Berliner³, Sergio Leal²

Affiliations

¹ Ophthalmic Consultants of Boston, Boston, MA, USA. jsheier@eyeboston.com.
² Bayer Consumer Care AG, Basel, Switzerland.
³ Regeneron Pharmaceuticals, Tarrytown, NY, USA.

PMID: 39805961
DOI: 10.1038/s41433-024-03543-x

No abstract available

Grants and funding